Company Description
Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The comp...
Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development.The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Valuation
Price to Sales Ratio
4.58
Price to Book Ratio
15.99
Price to Cash Flow Ratio
237.73
Enterprise Value to EBITDA
111.88
Enterprise Value to Sales
6.63
Efficiency
Total Asset Turnover
0.69
Liquidity
Current Ratio
6.35
Quick Ratio
6.00
Cash Ratio
5.47
Profitability
Gross Margin
71.35
Operating Margin
2.05
Pretax Margin
-15.93
Net Margin
-15.90
Return on Assets
-11.02
Return on Equity
-72.46
Return on Total Capital
1.59
Capital Structure
Total Debt to Total Assets
71.31
Officers and Executives
| Name | Age | Officer Since | Title |
|---|---|---|---|
| Mr. Mark L. Baum | 48 | 2006 | Chairman & Chief Executive Officer |
| Mr. Andrew R. Boll | 37 | 2011 | Chief Financial Officer & Secretary |
| Mr. Kim K.J Barratt | - | - | Chief Talent Officer |
| Dr. Dennis E. Saadeh | - | - | Chief Formulation Strategy |
| Mr. John P. Saharek | 60 | 2012 | Vice President-Commercialization |
Insider Actions
| 04/03/2023 |
Mark L. Baum Chief Executive Officer; Director |
117,633 | Derivative/Non-derivative trans. at $20.97 per share. | 2,466,764 |
| 04/03/2023 |
Mark L. Baum Chief Executive Officer; Director |
180,000 | Derivative/Non-derivative trans. at $8.99 per share. | 1,618,200 |
| 03/31/2023 |
Andrew R. Boll Chief Financial Officer |
34,442 | Derivative/Non-derivative trans. at $21.16 per share. | 728,792 |
| 03/31/2023 |
Andrew R. Boll Chief Financial Officer |
90,000 | Derivative/Non-derivative trans. at $6 per share. | 540,000 |
| 01/02/2023 |
Mark L. Baum Chief Executive Officer; Director |
35,179 | Derivative/Non-derivative trans. at $14.76 per share. | 519,242 |
| 01/02/2023 |
Andrew R. Boll Chief Financial Officer |
9,602 | Derivative/Non-derivative trans. at $14.76 per share. | 141,725 |
| 01/02/2023 |
Mark L. Baum Chief Executive Officer; Director |
88,000 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 01/02/2023 |
Andrew R. Boll Chief Financial Officer |
23,000 | Derivative/Non-derivative trans. at $0 per share. | 0 |
| 12/22/2022 |
Mark L. Baum Chief Executive Officer; Director |
25,000 | Acquisition at $13.39 per share. | 334,750 |
| 12/22/2022 |
Andrew R. Boll Chief Financial Officer |
2,500 | Acquisition at $13.54 per share. | 33,850 |
| 12/22/2022 |
R. Lawrence van Horn Director |
1,860 | Acquisition at $13.42 per share. | 24,961 |
| 12/21/2022 |
Martin A. Makary Director |
25,000 | Acquisition at $13.37 per share. | 334,250 |
| 12/14/2022 |
Opaleye Management, Inc. |
16,183 | Acquisition at $10.52 per share. | 170,245 |
| 12/14/2022 |
Opaleye Management, Inc. |
415,000 | Acquisition at $10.52 per share. | 4,365,800 |
| 09/30/2022 |
Richard L. Lindstrom Director |
40,000 | Disposition at $12.62 per share. | 504,800 |
| 09/28/2022 |
Opaleye Management, Inc. |
1,085 | Acquisition at $9.77 per share. | 10,600 |
| 09/28/2022 |
Opaleye Management, Inc. |
10,000 | Acquisition at $9.77 per share. | 97,700 |
| 04/13/2022 |
Opaleye Management, Inc. |
2,832 | Acquisition at $6.76 per share. | 19,144 |
| 04/13/2022 |
Opaleye Management, Inc. |
10,000 | Acquisition at $6.76 per share. | 67,600 |
| 04/12/2022 |
Opaleye Management, Inc. |
3,557 | Acquisition at $6.75 per share. | 24,009 |
| 04/12/2022 |
Opaleye Management, Inc. |
25,000 | Acquisition at $6.75 per share. | 168,750 |
MarketWatch News on HROW
-
Imprimis Pharma initiated as buy at B Riley FBR
- Ciara Linnane
-
Express Scripts opts for $1 alternative to Turing’s $750 Daraprim
- Jonathan D. Rockoff
-
Valeant’s use of specialty pharmacy channel is typical of the industry
- Francine McKenna
-
Duckburg Economics: Pricing and Scarcity in Drugs
- Barron's Online
Other News on HROW
-
A New Roster of Top Stock-Fund Managers
- The Wall Street Journal Interactive Edition
-
- Edgar Online - (EDG = 10Q, 10K)
-
Opaleye Management Inc. Buys 3, Sells 2 in 4th Quarter
- GuruFocus.com
-
Harrow Health, Inc. (HROW) Q3 2022 Earnings Call Transcript
- Seeking Alpha
-
- Edgar Online - (EDG = 10Q, 10K)
-
Private Capital Buys 4, Sells 1 in 2nd Quarter
- GuruFocus.com
-
- Edgar Online - (EDG = 10Q, 10K)
